(RTTNews) – Today’s Daily Dose brings you news about the first rolling review of a COVID-19 vaccine in the EU, reverse merger of privately held Chinook Therapeutics with Aduro, Enlivex Therapeutics’ positive top-line results of an investigator-initiated clinical trial of Allocetra in COVID-19 patients in severe/critical condition, FDA lifting the clinical hold on Solid Biosciences’ IGNITE DMD trial, and Vaccibody’s deal with Roche to develop neoantigen cancer vaccines.

Read on…

1. EU begins First Rolling Review of COVID-19 vaccine

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has started the ‘rolling review’ of AZD1222, the COVID-19 vaccine candidate, being developed by AstraZeneca plc (AZN) in collaboration with the University of Oxford.

This marks the first ‘rolling review’ of a COVID-19 vaccine, and the data being reviewed by the committee comes from laboratory studies (non-clinical data). The CHMP decided to start the rolling review of the AZD1222